ClinicalTrials.gg
CompletedNCT01696500Updated Jul 2, 2014

Phase III Clinical Trial of NPB-01 in Patients With Stevens-Johnson Syndrome/ Toxic Epidermal Necrolysis Unresponsive to Corticosteroids.

A Phase 3 interventional study of Intravenous immunoglobulin in Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis, sponsored by Nihon Pharmaceutical Co., Ltd. Completed at 1 site in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2014-07-02.

Sponsored by Nihon Pharmaceutical Co., Ltd · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
10
Allocation
Not applicable
Ages
20 Years and older
Sex
All
01

Study summary

Patients diagnosed with Stevens-Johnson syndrome and Toxic Epidermal Necrolysis were confirmed based on the investigators national diagnostic criteria. Patients who meet all inclusion criteria and do not conflict with the exclusion criteria will receive NPB-01 (intravenous immunoglobulin) 400mg/kg/day for five consecutive days. Subsequently, efficacy of NPB-01 for therapy of Stevens-Johnson syndrome and Toxic Epidermal Necrolysis will be evaluated the disease evaluation score et al.

As a safety endpoint, the safety of NPB-01 will be investigated the occurrence of adverse events by 20 days after the start of the study treatment.

02

Conditions studied

  • Stevens-Johnson Syndrome
  • Toxic Epidermal Necrolysis

Keywords

  • IVIG in Stevens-Johnson syndrome
  • Toxic Epidermal Necrolysis
  • Patients with Stevens-Johnson syndrome
  • Toxic Epidermal Necrolysis unresponsive to corticosteroids
03

In context

Stevens-Johnson Syndrome

40 studies on the registry are indexed under Stevens-Johnson Syndrome; 8 are open to participants now.

This study's planned enrollment of 10 is below the median of 20 across 24 interventional studies indexed under Stevens-Johnson Syndrome.

Browse Stevens-Johnson Syndrome studies →

Lead sponsor

Nihon Pharmaceutical Co., Ltd is the lead sponsor of 19 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients who the disease evaluation score is more than 14 at study medication received.
  2. Patients with over 20mg/day(Prednisolone) at study medication received and continued this treatment more than 2 days.
  3. Patients with treatment effect is insufficiency before study medication received and need additional treatment.
  4. Patients aged more than twenty years old at .

Exclusion criteria

Exclusion Criteria:

  1. Patients who the SCORTEN score is more than 4 at study medication received.
  2. Patients with multiple organ failure at study medication received.
  3. Patients with severe respiratory disorder at study medication received.
  4. Patients with Drug-induced syndrome (DIHS) at .
  5. Patients with during treatment at informed consent.
  6. Patients treated with dosage is change at 2 days before study medication received.
  7. Patients treated with corticosteroids pulse therapy(including semi-pulse therapy) at 2 days before study medication received.
  8. Patients treated with plasmapheresis at 2 days before study medication received.
  9. Patients treated with high-dose intravenous immunoglobulin at 28 days before informed consent.
  10. Patients with history of shock or hypersensitivity for NPB-01.
  11. Patients with IgA deficiency.
  12. Patients with severe impaired liver function diagnosed virus hepatitis or cirrhosis et al.
  13. Patients with more than 2mg/dL serum creatinine.
  14. Patients with severe cerebro- or cardiovascular disorders.
  15. Patients with high risk of thromboembolism.
  16. Patients with hemolytic/hemorrhagic anemia.
  17. Patients with severe decreased cardiac function.
  18. Patients with decreased less than 75,000/μL..
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
10 participants (estimated)

Study arms

  • Experimental
    NPB-01

    Drug: Intravenous immunoglobulin

06

What researchers measure

Primary outcomes

  1. disease evaluation score

    Time frame: 7 days

Secondary outcomes

  1. disease evaluation score

    Time frame: 4 ,10 ,20 days

  2. avulsed skin area

    Time frame: 20 days

  3. erythematous area

    Time frame: 20 days

07

Study locations

1 site
  • Nihon Pharmaceutical Co., Ltd
    Tokyo, 101-0031, Japan
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2012, a primary completion of Jun 2014 and a completion of Jun 2014. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 20, 2012
First posted
Oct 1, 2012
Start
Oct 2012
Primary completionActual
Jun 2014
CompletionActual
Jun 2014
Last update
Jul 2, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 2, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01696500
Lead sponsor
Nihon Pharmaceutical Co., Ltd
Responsible party
Sponsor
First posted
Oct 1, 2012
Start date
Oct 2012
Primary completion
Jun 2014
Completion
Jun 2014
Last update
Jul 2, 2014

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Immunoglobulins, Intravenous

Start the discussion